**Public Health Advisory Issued as New COVID-19 Variant Drives Infection Surges in Popular Destinations**
Health authorities around the globe have issued cautionary statements following the emergence of a new COVID-19 strain, NB.1.8.1, which is reportedly responsible for a significant uptick in case numbers across several tourism hotspots. The World Health Organisation (WHO) has recently reclassified this variant as a “variant under monitoring”, citing concerns about its swiftly increasing prevalence.
According to data compiled in late April 2025, NB.1.8.1 accounted for approximately 10.7% of all reported cases worldwide—a substantial leap from just 2.5% a month earlier. This new strain has already become the dominant form of COVID-19 in areas such as Hong Kong and mainland China, alarming public health officials and researchers alike.
Experts analysing the strain have pointed to multiple genetic mutations which may enable NB.1.8.1 to infect human cells more adeptly than its predecessor strains. Associate Professor Lara Herrero, an authority on virology at Griffith University, commented on the development: “The accumulated mutations in NB.1.8.1 may help the virus latch onto and enter cells more efficiently, possibly enhancing its transmissibility compared to earlier iterations of COVID-19.”
Initial findings have shown that the variant has been identified in a host of countries, including Australia, the United States, and possibly the United Kingdom. Professor Herrero also highlighted the upping concern that individuals infected with NB.1.8.1 could be more likely to transmit the virus to others, owing to its apparent ability to partially escape immunity, whether acquired from previous infection or vaccination. She said, “Greater ease of spread and partial immune evasion likely underpin the rapid rise in NB.1.8.1 cases seen in recent surveillance data.”
However, the WHO has not yet found any evidence suggesting the variant causes more severe illness than others currently circulating. Symptoms appear in line with those associated with other Omicron subvariants. These include sore throat, fatigue, fever, mild cough, muscle pain, and nasal congestion, though gastrointestinal issues have also been observed in some instances.
WHO has published a report outlining evolving variant patterns since January 2025. At the beginning of the year, variant XEC led global cases, succeeded by KP.3.1.1, and later LP.8.1, which gained prominence by March. In recent weeks, the emergence of NB.1.8.1 has driven new dynamics, seeing LP.8.1 numbers begin to dip as NB.1.8.1 surged ahead.
Particularly significant increases have been detected in the Eastern Mediterranean—a region that encompasses major travel destinations such as Egypt—as well as throughout South East Asia, including Thailand and the Maldives. Cambodia, Singapore, and Hong Kong are also experiencing a rise in infections associated with the new variant.
In its latest briefing, WHO reiterated the importance for national authorities to maintain vigilance. The organisation advised governments to adjust their public health responses in line with changing epidemiological trends and continue bolstering systems for managing COVID-19 and other respiratory viruses. Public health recommendations include persisting with COVID-19 vaccination campaigns pursuant to WHO guidance.
Crucially, the global health body has stopped short of recommending any new travel or trade restrictions at this stage. “On current risk evaluations, WHO advises against the implementation of travel or commerce limitations specifically in response to NB.1.8.1,” the organisation stated, urging a more measured and strategic public health approach.
While communities worldwide continued to adapt to the shifting COVID-19 landscape, experts agree that ongoing surveillance and transparent reporting will be essential in tracking NB.1.8.1 and mitigating potential impacts. Holidaymakers planning trips to affected areas are encouraged to stay informed and adhere to local health advisories as the situation continues to develop.